# NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial

> **NCT05569811** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **SOLTI Breast Cancer Research Group** · enrollment: 120 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Patritumab deruxtecan
- **DRUG:** Chemotherapy
- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT05569811
- **Lead sponsor:** SOLTI Breast Cancer Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-25
- **Primary completion:** 2025-03-31
- **Final completion:** 2030-07-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05569811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05569811, "NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05569811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*